DMARDs, used to modify the disease course and prevent joint damage in RA, are categorized into traditional (e.g., methotrexate [MTX], sulfasalazine, hydroxychloroquine, and leflunomide) and biologic DMARDs (e.g., TNF-α inhibitors [TNFis], IL-6 inhibitors, and B-cell depletion agents) [9]. This evidence concerns the gene IL6 and rheumatoid arthritis.